Nested model reveals potential amplification of an HIV epidemic due to drug resistance

Epidemics

Volumn 5, Issue 1, 2013, Pages 34-43

  Saenz, Roberto A ^a,b   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

Drug resistance; HIV; Nested model

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; DYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MATHEMATICAL MODEL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MEDICATION ADHERENCE; MODELS, THEORETICAL; PREVALENCE; SWITZERLAND;

EID: 84870942425     PISSN: 17554365     EISSN: 18780067     Source Type: Journal    
DOI: 10.1016/j.epidem.2012.11.002     Document Type: Article

References (33)

1. Baggaley R.F., Garnett G.P., Ferguson N.M. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Medicine 2006, 3:e124.
2. Bangsberg D.R., Acosta E.P., Gupta R., Guzman D., Riley E.D., Harrigan P.R., Parkin N., Deeks S.G. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006, 20:223-231.
3. Barth R.E., van der Loeff M.F.S., Schuurman R., Hoepelman A.I., Wensing A.M. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. The Lancet Infectious Diseases 2010, 10:155-166.
4. Blower S., Bodine E., Kahn J., McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005, 19:1-14.
5. Bonhoeffer S., Coffin J.M., Nowak M.A. Human immunodeficiency virus drug therapy and virus load. Journal of Virology 1997, 71:3275-3278.
6. Bonhoeffer S., Nowak M.A. Pre-existence and emergence of drug resistance in HIV-1 infection. Proceedings of the Royal Society B 1997, 264:631-637.
7. Clavel F., Hance A.J. HIV drug resistance. New England Journal of Medicine 2004, 350:1023-1035.
8. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., Hakim J.G., Kumwenda J., Grinsztejn B., Pilotto J.H., Godbole S.V., Mehendale S., Chariyalertsak S., Santos B.R., Mayer K.H., Hoffman I.F., Eshleman S.H., Piwowar-Manning E., Wang L., Makhema J., Mills L.A., de Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha T.E., Nielsen-Saines K., Celentano D., Essex M., Fleming T.R. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 2011, 365:493-505.
9. Dodd P.J., Garnett G.P., Hallett T.B. Examining the promise of HIV elimination by " Test and Treat" in Hyper-Endemic settings. AIDS 2010, 24:729-735.
10. van den Driessche P., Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical Biosciences 2002, 180:29-48.
11. Fideli U.S., Allen S.A., Musonda R., Trask S., Hahn B.H., Weiss H., Mulenga J., Kasolo F., Vermund S.H., Aldrovandi G.M. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Research and Human Retroviruses 2001, 17:901-910.
12. Fraser C., Hollingsworth T.D., Chapman R., de Wolf F., Hanage W.P. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:17441-17446.
13. Granich R., Kahn J.G., Bennett R., Holmes C.B., Garg N., Serenata C., Sabin M.L., Makhlouf-Obermeyer C., De Filippo Mack C., Williams P., Jones L., Smyth C., Kutch K.A., Ying-Ru L., Vitoria M., Souteyrand Y., Crowley S., Korenromp E.L., Williams B.G. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE 2012, 7:e30216.
14. Hamers R.L., Schuurman R., Sigaloff K.C., Wallis C.L., Kityo C., Siwale M., Mandaliya K., Ive P., Botes M.E., Wellington M., Osibogun A., Wit F.W., van Vugt M., Stevens W.S., de Wit T.F.R. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. The Lancet Infectious Diseases 2011, 12:307-317.
15. Hamers R.L., Wallis C.L., Kityo C., Siwale M., Mandaliya K., Conradie F., Botes M.E., Wellington M., Osibogun A., Sigaloff K.C.E., Nankya I., Schuurman R., Wit F.W., Stevens W.S., van Vugt M., de Wit T.F.R. HIV-1 drug resistance in antiretroviral-naïve individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. The Lancet Infectious Diseases 2011, 11:750-759.
16. Hollingsworth T.D., Anderson R.M., Fraser C. HIV-1 transmission, by stage of infection. Journal of Infectious Diseases 2008, 198:687-693.
17. Hué S., Gifford R.J., Dunn D., Fernhill E., Pillay D. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. Journal of Virology 2009, 83:2645-2654.
18. Jain V., Sucupira M.C., Bacchetti P., Hartogensis W., Diaz R.S., Kallas E.G., Janini L.M., Liegler T., Pilcher C.D., Grant R.M., Cortes R., Deeks S.G., Hecht F.M. Differential persistence of transmitted HIV-1 drug resistance mutation classes. Journal of Infectious Diseases 2011, 203:1174-1181.
19. Joint United Nations Programme on HIV/AIDS, 2011. World AIDS Day Report. Available from: (accessed 22.05.12). http://www.unaids.org/en/resources/documents/2011/.
20. Kitayimbwa J.M., Mugisha J.Y.T., Saenz R.A. The role of backward mutations on the within-host dynamics of HIV-1. Journal of Mathematical Biology 2012, 10.1007/s00285-012-0581-2.
21. Little S.J., Frost S.D.W., Wong J.K., Smith D.M., Pond S.L.K., Ignacio C.C., Parkin N.T., Petropoulos C.J., Richman D.D. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. Journal of Virology 2008, 82:5510-5518.
22. Margeridon-Thermet S., Shafer R.W. Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C. Viruses 2010, 2:2696-2739.
23. Mideo N., Alizon S., Day T. Linking within- and between-host dynamics in the evolutionary epidemiology of infectious diseases. Trends in Ecology and Evolution 2008, 23:511-517.
24. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
25. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
26. Sánchez M., Grant R., Porco T., Gross K., Getz W. A decrease in drug resistance levels of the HIV epidemic can be bad news. Bulletin of Mathematical Biology 2005, 67:761-782.
27. Smith R.J., Okano J.T., Kahn J.S., Bodine E.N., Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010, 327:697-701.
28. Stafford M.A., Corey L., Cao Y., Daar E.S., Ho D.D., Perelson A.S. Modeling plasma virus concentration during primary HIV infection. Journal of Theoretical Biology 2000, 203:285-301.
29. Supervie V., Barret M., Kahn J.S., Musuka G., Moeti T.L., Busang L., Blower S. Modeling dynamic interactions between pre-exposure prophilaxis interventions and treatment programs: predicting HIV transmission and resistance. Scientific Reports 2011, 1.
30. Thieme H.R., Castillo-Chávez C. How may infection-age-dependent infectivity affect the dynamics of HIV/AIDS?. SIAM Journal on Applied Mathematics 1993, 53:1447-1479.
31. Wagner B.G., Blower S. Universal access to HIV treatment versus universal 'test and treat': Transmission, drug resistance and treatment costs. PLoS One 2012, 7:e41212.
32. Wittkop L., Günthard H.F., de Wolf F., Dunn D., Cozzi-Lepri A., de Luca A., Kücherer C., Obel N., von Wyl V., Masquelier B., Stephan C., Torti C., Antinori A., García F., Judd A., Porter K., Thiébaut R., Castro H., van Sighem A.I., Colin C., Kjaer J., Lundgren J.D., Paredes R., Pozniak A., Clotet B., Phillips A., Pillay D., Chêne G. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. The Lancet Infectious Diseases 2011, 11:363-371.
33. World Health Organization Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach (2010 revision) 2010, WHO, Geneva, Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (accessed 13.06.12).